ADME characterization is a critical step in the drug development process as a means for measuring the kinetics of drug exposure and overall drug performance and toxicity within an organism. Traditionally used during the later stages of lead optimization, more organizations are demanding earlier ADME-Tox studies to reduce late phase drug failures and the significant costs associated. Using the Echo liquid handler researchers are successfully implementing comprehensive ADME-Tox screens into the early stages of drug discovery ensuring that drug candidates are well characterized and development costs are minimized.
Key Benefits:
- Easily lower reaction volumes and increase throughput for a range of ADME-Tox assays
- Multiplexing and dose-response with direct dilution is simple using Echo software applications
- Walk-up automation allows all lab personally to get the benefits of the Echo liquid handler with minimal training
Literature:
Publications
CYP3A Time Dependent Inhibition Risk Assessment Validated With 400 Reference Drugs, A. Simmerlin, et. al, Novartis, Drug Metabolism and Disposition
A Miniaturized Homogenous Assay of Mitochondrial Membrane Potential, A. Vongs, et. al, Assay and Drug Discovery Technologies
Application Notes
Miniaturized Luminescent Metabolism Profiling Assays
A-350 Bioluminescence for Drug Metabolism Profiling (Joint with Promega and featured in 'Promega Cell Notes')
Featured Posters
A Miniaturized and Automated P450-Glo™ Screening System Using the Echo® Liquid Handler - SLAS2012 (with Promega Corp.)
Miniaturized Luminescent Metabolism Profiling Assays,
Cytochrome P-450 Activity Screening in Low Volume 384 & 1536 Well Formats using Promega's P-450 Glo Assays
Product Brochures
Echo Liquid Handler Brochure
Access Laboratory Workstation Brochure
POD Automation Platform Brochure